• 2008: Master’s degree cum laude in Medicine, University of Rome La sapienza
• 2015: Postgraduate degree cum laude in Nuclear Medicine, University of Rome Tor Vergata
• 2016: PhD cum laude in Applied Biotechnology and Translational Medicine,University of Rome Tor Vergata
• 2016: Researcher, Department of Biomedicine and Prevention, University of Rome Tor Vergata
• 2016: Lecturer in the School of Specialization in Nuclear Medicine, University of Rome Tor Vergata, MED/36
• 2016: Lecturer in the School of Specialization in Radiology, University of Rome Tor Vergata, MED/36
• 2016: Lecturer graduate course in Health Services Prevention and Nursing, humanities and psycho-pedagogical sciences, University of Rome Tor Vergata, MED/36
• 2016: Lecturer Bachelor of Medicine course in English language (International Medical School), University of Rome Tor Vergata, MED/36
• 2016: Lecturer Bachelor of Medicine, University of Rome Tor Vergata, MED/36
• 2017: Nuclear medicine physician, UOC Nuclear Medicine, Policlinico Tor Vergata, Rome
• 2017: Lecturer, Nostra Signora del Buon Consiglio, Catholic University of Tirana, MED/36
• 2018: Lecturer in the doctoral course Medical Biotechnology and Translational Medicine, University of Rome Tor Vergata, MED/36
• 2021: Lecturer in the School of Specialization in Diseases of the Cardiovascular System, University of Rome Tor Vergata, MED/36
• 2022: Adjunct professor MED/36, Faculty of Medicine, Saint Camillus University, Rome
• 2022: Associate professor MED/36, Department of Biomedicine and Prevention, Faculty of Medicine, University of Rome Tor Vergata

Prof. Agostino Chiaravalloti is the author of more than 130 scientific articles published in journals of international relevance and has participated as a speaker in more than 100 events of national and international importance.

His main fields of interest are the study by PET and SPECT of neurodegenerative syndromes and oncological diseases and early diagnosis by advanced statistical methods.

Prof. Agostino Chiaravalloti is also scientific leader of several European Horizon 2020 projects on the topics of telemedicine, artificial intelligence and home monitoring of patients with neurodegenerative diseases.